Actera, a supplier of skincare products, receives private fund Arcline Strategy.

Cosmetics industry is facing more and more urgent demand for raw material supply, which enables us to further develop cutting-edge products. Private equity fund Arcline Investment Management (hereinafter referred to as Arcline) announced a strategic investment in Actera Ingredients (hereinafter referred to as Actera), a supplier of protective raw materials, but did not publish specific financial terms.

Actera provides raw materials and formulation technology for personal care products. Its raw materials are mainly divided into three categories, including functional and sensory components, active and anti-aging components, and natural preservatives. These ingredients and recipes can be applied to cosmetics, body and hair care products, household products, perfume, etc. Actera's raw materials have the characteristics of high performance, cleanliness and naturalness. These are the decisive factors to promote market innovation, and all of them have passed clinical research and scientific testing, so that customers'products can fully benefit from the effectiveness of their raw materials. Dan Winn, CEO of Actera, said: "We are very happy to work with Arcline, who will support our growing product portfolio and expand our team to better serve our customers. The demand for raw materials in the cosmetics industry is becoming more and more urgent, which enables us to further develop cutting-edge products.

Arcline commented: "Consumers begin to attach importance to and understand the science behind personal care and beauty consumer products. The cosmetics industry is rapidly adapting to new changes, and people are pursuing more sustainable chemical composition and cleaner ingredients from biological sources. Actera is at the forefront of cleaner ingredients and will provide us with a platform to continue investing in this fast-changing industry.

About Arcline

Arcline Investment Management is a growing private equity investment company, which manages $1.5 billion in capital and invests mainly in leading companies in niche markets, including life sciences, industrial technology and special chemicals. Arcline seeks to invest in companies with EBITDA (pre-tax depreciation and pre-amortization profits) amounting to between $10 million and $100 million, with a valuation of up to $1 billion. Arcline's vision is to identify and unlock the company's potential.